Avoid common mistakes on your manuscript.
Dear Editor,
We would like to discuss " mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients [1].” Albiol et al. reported that the mRNA-1273 SARS-CoV-2 vaccination is safe in recent HCT patients and contends that perceptions of COVID-19 risk diminish over time [1]. The effectiveness of the COVID-19 immunization may be influenced by a number of variables. There are a variety of doses and administration techniques available. Compared to the typical, healthy vaccine recipient, patients who are taking prescription medications or who have pre-existing medical conditions may be more susceptible to immunizations. We can all agree that the idea of a COVID-19 vaccination is fantastic. The prevalence of asymptomatic COVID-19 may contribute to the lack of symptoms [2]. Testing is frequently forgone in order to rule out a prior, asymptomatic COVID-19 infection. Only having a past illness history is insufficient. Various laboratory tests need to be performed. To further comprehend the underlying immunological issues that a vaccine recipient is experiencing, specific laboratory testing should be used. The effectiveness of the COVID-19 vaccine can be predicted by consistently observing the underlying immunological abnormalities of vaccination recipients. This is an important factor to consider when evaluating the efficacy or safety of a vaccination. Despite the fact that clinical data on pre-vaccination health or immunological status is typically scarce, a number of clinical articles have shown the effectiveness, safety, or clinical importance of the COVID-19 vaccine. Furthermore, the likelihood of cross-contamination with an undetected SARS-Co-V2 infection cannot be entirely ruled out. Another recent study [3] found a link between inherited genetic diversity and the immunological responses of vaccination recipients. If more research is envisaged, the effects of the genetic polymorphism should be evaluated.
References
Albiol N, Barata A, Aso O, Gómez-Pérez L, Triquell M, Roch N, Lázaro E, Esquirol A, González I, López-Contreras J, Sierra J, Martino R, García-Cadenas I (2022) mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. https://doi.org/10.1007/s00520-022-07376-w. Online ahead of print
Joob B, Wiwanitkit V (2020) Letter to the Editor: Coronavirus Disease 2019 (COVID-19), Infectivity, and the Incubation Period. J Prev Med Public Health 53(2):70
Čiučiulkaitė I, Möhlendick B, Thümmler L, Fisenkci N, Elsner C, Dittmer U, Siffert W, Lindemann M (2022) GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine. Front Genet. 13:932043
Author information
Authors and Affiliations
Contributions
RM ideas, writing, analyzing, approval for submission VW ideas, supervising, approval for submission
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mungmunpuntipantip, R., Wiwanitkit, V. Comment on “SARS-CoV-2 vaccine safety and COVID-19 risk perception in hematopoietic stem cell transplant recipients”. Support Care Cancer 32, 51 (2024). https://doi.org/10.1007/s00520-023-08237-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00520-023-08237-w